Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nuvamid SA is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are assigned to 3 distinct examiners, ensuring that each matter receives an independent review. These examiners are located within 2 distinct art units, which suggests some level of technical grouping for the company's active filings.
KRISHNAN, GANAPATHY is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending office action. Since there are 3 distinct examiners for the 3 pending office actions, the workload is evenly distributed among them. Practitioners should note that the 3 pending office actions are subject to the specific rules and practices of 2 distinct art units.
The distribution of 3 pending office actions across 3 distinct examiners means that there is no single point of contact for the majority of the portfolio. Each of the 3 pending office actions, including the one with KRISHNAN, GANAPATHY, must be managed according to the examiner's individual style. This 3-action portfolio in Biotechnology & Pharmaceuticals is spread across 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.8% | +1.1% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| BRANDSEN, BENJAMIN MICHAEL | 1 | 60.2% | +18.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570879 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | KRISHNAN, GANAPATHY | — |
| 17919559 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | HAVLIN, ROBERT H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919559 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | HAVLIN, ROBERT H | — |
| 17785631 | NOVEL NICOTINAMIDE DI-NUCLEOTIDE DERIVATIVES AND USE THEREOF | BRANDSEN, BENJAMIN MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570879 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | KRISHNAN, GANAPATHY | 1693 | §103§112 | Final Rejection | — | Pending | Dec 15, 2023 |
| 17919559 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | HAVLIN, ROBERT H | 1626 | §102§103Other | Non-Final OA | — | Pending | Oct 18, 2022 |
| 17785631 | NOVEL NICOTINAMIDE DI-NUCLEOTIDE DERIVATIVES AND USE THEREOF | BRANDSEN, BENJAMIN MICHAEL | 1693 | §112Other | Non-Final OA | — | Pending | Jun 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial